Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
Clinical trial NCT07550920 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07550920
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-10
- Primary completion
- 2027-03-30
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.